Alzheimer DiseasePhase 3NCT00996918
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 study testing Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg in people with Alzheimer Disease, run by Pfizer at 82 sites in 17 countries.
Trial summary
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Read more about this study
- Who is it for?
- Ages 51 years and older
- Conditions the study is for
- Alzheimer Disease
- What is being tested?
- Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 198 participants
- Where
- 82 sitesin 17 countries
- Study dates
- Dec 2009to Nov 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 51 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
- Mini-Mental Status Examination (MMSE) >=10 at screening
- Caregiver able to attend all clinic visits with subject
Who cannot join
- Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
- Any significant brain MRI abnormality.
- Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening
Trial locations and contacts
82 sites in 17 countries.
82 sites in 17 countries
Spain16 sites
Pfizer Investigational Site
Barcelona, Barcelona, 08003
Pfizer Investigational Site
Barcelona, Barcelona, 08014
Pfizer Investigational Site
Barcelona, Barcelona, 08034
Pfizer Investigational Site
Barcelona, Barcelona, 08041
Pfizer Investigational Site
Burgos, Burgos, 09006
Pfizer Investigational Site
Elche, Alicante, 03203
Pfizer Investigational Site
Madrid, Madrid, 28006
Pfizer Investigational Site
Madrid, Madrid, 28034
Pfizer Investigational Site
Madrid, Madrid, 28040
Pfizer Investigational Site
Madrid, Madrid, 28041
Pfizer Investigational Site
Madrid, Madrid, 28046
Pfizer Investigational Site
Madrid, 28006
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, 07010
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, 07014
Pfizer Investigational Site
Plasencia, Caceres, 10600
Pfizer Investigational Site
Terrassa, Barcelona, 08221
France13 sites
Pfizer Investigational Site
Caen, 14033
Pfizer Investigational Site
Dijon, France, 21000
Pfizer Investigational Site
Lille, France, 59037
Pfizer Investigational Site
Marseille, France, 13000
Pfizer Investigational Site
Marseille, 13885
Pfizer Investigational Site
Montpellier, 34295
Pfizer Investigational Site
Nantes - Saint Herblain, 44093
Pfizer Investigational Site
Nice, 06000
Pfizer Investigational Site
Paris, France, 75013
Pfizer Investigational Site
Poitiers, 86021
Pfizer Investigational Site
Rennes, 35000
Pfizer Investigational Site
Rouen, 76031
Pfizer Investigational Site
Toulouse, 31059
Japan13 sites
Pfizer Investigational Site
Aichi
Pfizer Investigational Site
Chiba
Pfizer Investigational Site
Fukuoka
Pfizer Investigational Site
Hiroshima
Pfizer Investigational Site
Hyōgo
Pfizer Investigational Site
Kagawa
Pfizer Investigational Site
Kanagawa
Pfizer Investigational Site
Kyoto
Pfizer Investigational Site
Nagano
Pfizer Investigational Site
Okayama
Pfizer Investigational Site
Osaka
Pfizer Investigational Site
Shizuoka
Pfizer Investigational Site
Tokyo
United Kingdom9 sites
Pfizer Investigational Site
Brighton, BN2 5BE
Pfizer Investigational Site
Glasgow, G20 OXA
Pfizer Investigational Site
London, London, SE5 9RS
Pfizer Investigational Site
London, W6 8RF
Pfizer Investigational Site
Newcastle upon Tyne, NE4 5PL
Pfizer Investigational Site
Penarth, CF64 2XX
Pfizer Investigational Site
Sheffield, S10 2JF
Pfizer Investigational Site
Sheffield, S35 8QS
Pfizer Investigational Site
Swindon, SN3 6BW
Australia5 sites
Pfizer Investigational Site
Adelaide, South Australia, 5000
Pfizer Investigational Site
Heidelberg Heights, Victoria, 3081
Pfizer Investigational Site
Hornsby, New South Wales, 2077
Pfizer Investigational Site
Nedlands, Western Australia, 6009
Pfizer Investigational Site
Woodville South, South Australia, 5011
Poland5 sites
Pfizer Investigational Site
Bydgoszcz, 85-796
Pfizer Investigational Site
Krakow, 31-531
Pfizer Investigational Site
Poznan, Poland, 61-289
Pfizer Investigational Site
Warsaw, 01-211
Pfizer Investigational Site
Warsaw, 02-097
Belgium3 sites
Pfizer Investigational Site
Antwerp, 2020
Pfizer Investigational Site
Brussels, 1200
Pfizer Investigational Site
Edegem, 2650
Portugal3 sites
Pfizer Investigational Site
Amadora, Amadora, 2700-276
Pfizer Investigational Site
Coimbra, Coimbra District, 3000-075
Pfizer Investigational Site
Lisbon, Lisbon District, 1649-028
Chile2 sites
Pfizer Investigational Site
Santiago, Chile, 7530193
Pfizer Investigational Site
Santiago, Chile, 7630000
Finland2 sites
Pfizer Investigational Site
Kuopio, FIN-70210
Pfizer Investigational Site
Turku, 20520
Italy2 sites
Pfizer Investigational Site
Milan, 20133
Pfizer Investigational Site
Roma, 00179
Netherlands2 sites
Pfizer Investigational Site
's-Hertogenbosch, 5223 GZ
Pfizer Investigational Site
Leeuwarden, 8934 AD
Slovakia2 sites
Pfizer Investigational Site
Bratislava, 825 56
Pfizer Investigational Site
Rimavská Sobota, 979 12
South Africa2 sites
Pfizer Investigational Site
Johannesburg, Gauteng, 2196
Pfizer Investigational Site
Pretoria, Gauteng, 0081
Switzerland1 site
Pfizer Investigational Site
Basel, Canton of Basel-City, CH-4031
About this study
Official title: A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.
- Conditions
- Alzheimer Disease
- Being tested
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Keywords
- antibody
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bapineuzumab 0.5 mg/kgDrug
Also called AAB-001
Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Bapineuzumab 1.0 m/kgDrug
Also called AAB-001
I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
| Study group | Role | What they receive |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | Experimental | bapineuzumab Receives: Drug: Bapineuzumab 0.5 mg/kg |
| Bapineuzumab 1.0 m/kg | Experimental | bapineuzumab Receives: Drug: Bapineuzumab 1.0 m/kg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Reporting a Serious Adverse Event.
Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.
Measured: Up to Week 195
Secondary outcomes (8)
Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Measured: Weeks 13, 26, 39, 52 and 78
Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Measured: Weeks 13, 26, 39, 52 and 78
Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement
Measured: Weeks 13, 26, 39, 52 and 78
Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78
The DAD measures instrumental and basic activities of daily living in participants with AD. The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement
Measured: Weeks 13, 26, 39, 52 and 78
Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score (range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.
Measured: Weeks 26, 52 and 78
Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, night-time behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.
Measured: Weeks 26, 52 and 78
Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state.
Measured: Weeks 6, 19, 32, 45 and 78
Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state
Measured: Weeks 6, 19, 32, 45 and 78
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2009 (estimated)
- Study startDec 2009
- Primary completionNov 2012
- Study completionNov 2012
Why it stopped: The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 198 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00996918
- Sponsor's protocol ID
- 3133K1-3002
- Other IDs
- B2521003
- Status last verified
- Nov 2013
- First submitted
- 14 Oct 2009
- Last updated
- 1 Jan 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.
PubMed 27334799
Study at a glance
From the registry record, last updated by the sponsor on 1 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000
- ClinicalTrials.gov ID
- NCT00996918
- Acronym / sponsor ID
- 3133K1-3002
- Conditions
- Alzheimer Disease
- Keywords
- antibody
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
- Enrolment
- 198 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Dec 2009
- Primary completion
- Nov 2012 (actual)
- Study completion
- Nov 2012 (actual)
- First posted
- 16 Oct 2009 (estimated)
- Results
- Posted 1 Jan 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bapineuzumab 0.5 mg/kg | Experimental | Drug: Bapineuzumab 0.5 mg/kgbapineuzumab |
| Bapineuzumab 1.0 m/kg | Experimental | Drug: Bapineuzumab 1.0 m/kgbapineuzumab |
Who may qualify
- Ages
- 51 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
- Mini-Mental Status Examination (MMSE) >=10 at screening
- Caregiver able to attend all clinic visits with subject
Key exclusion criteria (3 listed)
- Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
- Any significant brain MRI abnormality.
- Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bapineuzumab 0.5 mg/kgAlso: AAB-001Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions. | Drug | Bapineuzumab 0.5 mg/kg |
| Bapineuzumab 1.0 m/kgAlso: AAB-001I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions. | Drug | Bapineuzumab 1.0 m/kg |
Primary outcome
Number of Participants Reporting a Serious Adverse Event.
Time frame: Up to Week 195
Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.
8 secondary outcomes
Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.
Time frame: Weeks 13, 26, 39, 52 and 78
Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.
Time frame: Weeks 13, 26, 39, 52 and 78
Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
Time frame: Weeks 13, 26, 39, 52 and 78
Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78
Time frame: Weeks 13, 26, 39, 52 and 78
Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.
Time frame: Weeks 26, 52 and 78
Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.
Time frame: Weeks 26, 52 and 78
Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.
Time frame: Weeks 6, 19, 32, 45 and 78
Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.
Time frame: Weeks 6, 19, 32, 45 and 78
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jan 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 27334799Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
82 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg in people with Alzheimer Disease, run by Pfizer at 82 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 82 sites in Spain, France, Japan, United Kingdom, Australia and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Jan 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Reporting a Serious Adverse Event. (time frame: Up to Week 195). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00996918, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jan 2014.